A study of 38,723 people with type 2 diabetes found the SGLT2 inhibitors canagliflozin, dapagliflozin and empagliflozin were associated with reduced risk for kidney disease-related mortality, dialysis or transplantation. The findings, published in The Lancet Diabetes & Endocrinology, showed that SGLT2 inhibitor use was also associated with reduced risk for acute kidney injury and end-stage kidney disease.
Study shows SGLT2 inhibitors' renoprotective effect in diabetes
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.